Assisted Dying: Pioneers, Leaders, and the Question of Guardrails

Opening: One Death, Many Questions

Physician-assisted suicide has moved from a rare experiment at the margins of medicine to a growing feature of end-of-life care in many places. Yet the core questions remain unresolved: who should have access, under what safeguards, and whether doctors should be involved at all. John Maa’s recent account of watching his friend die through physician-assisted suicide brings these questions out of theory and into a living room, where a man with advanced pancreatic cancer drinks a lethal cocktail while his friends hold his hand and listen to his favorite song.

Maa describes not only his friend’s suffering but also the practical burdens: high out-of-pocket costs, the emotional impact on loved ones, and the uncertainty about whether physicians should do more to protect life, seek new treatments, or step back from the role of ending life. His story is one doorway into a wider international debate.

Historical Pioneers in Assisted Dying

Assisted dying did not emerge everywhere at once. Historically, a few jurisdictions acted decades before others and created models that still shape the debate.

• Switzerland is often cited as the earliest pioneer in assisted suicide, with legal space carved out as far back as the early 1940s. That framework allowed assistance in dying so long as the motive was not selfish, and it later gave rise to organizations that support people at the end of life, including some from abroad.

• In the United States, Oregon became the first state to adopt a physician-assisted dying law in the 1990s, the Death with Dignity Act, aimed at terminally ill patients who self-administer prescribed medication. That law, implemented in 1997, became the template for similar statutes elsewhere.

• The Netherlands is widely described as the first country to formally legalize euthanasia in the early 2000s, under strict conditions and reporting requirements. Belgium followed with its own euthanasia law, helping to establish Europe’s best-known euthanasia regimes.

These pioneers answered a question that had been mostly theoretical: can a modern legal system openly permit doctors or others to help people die without collapsing the boundaries between care and killing? Their answer was “yes, under conditions.”

Who Is Ahead Today in Access?

Today, the map of assisted dying looks very different. Several countries and subnational jurisdictions have adopted some form of assisted suicide or euthanasia, but the breadth of access varies greatly.

• Canada’s medical assistance in dying (MAID) regime is frequently noted as one of the more permissive contemporary frameworks, covering a broader range of medical conditions than the early U.S. state laws and continuing to evolve.

• Across Europe, a small group of states (such as the Netherlands, Belgium, Luxembourg, and others) now allow euthanasia or assisted dying under defined safeguards, often beyond narrow terminal-illness criteria.

• In the U.S., multiple states and Washington, D.C. have joined Oregon in legalizing physician-assisted dying, but the eligibility rules typically remain narrower, focused mainly on terminal illness and a short expected time to live.

In this sense, Switzerland is the historical pioneer, while countries like Canada and some European states are currently “ahead” in the breadth and operational scale of assisted dying. The spread is uneven, and there is no global consensus.

Why Assisted Dying Is Considered Necessary

Supporters of assisted dying often begin from the same point that Maa describes: the reality of severe, irreversible suffering at the end of life. His friend’s pancreatic cancer had progressed, treatments had failed, bowel obstructions required repeated hospitalization, and surgeons said nothing more could be done. In such situations, proponents argue that:

• Autonomy matters. A competent adult facing unbearable suffering should have the right to choose the timing and manner of death rather than be forced into prolonged decline.

• Compassion matters. When medicine can no longer cure or substantially relieve suffering, helping a patient avoid a drawn-out, painful end may be seen as a continuation of care rather than an abandonment of it.

• Reality matters. Even with good hospice and palliative care, some symptoms, losses of dignity, or forms of distress remain hard to control, and waiting can mean months of profound discomfort.

From this perspective, assisted dying is presented as a last-resort option for people whose lives have become dominated by suffering and for whom no realistic medical improvement is expected.

How Help Is Distributed Between Indications

Different systems distribute access to assisted dying across medical indications in very different ways. Common patterns include:

• Terminal cancer: In many regimes, advanced cancer is the leading indication for assisted dying, reflecting high symptom burden, poor prognosis, and patients’ awareness of progressive decline. Maa’s friend with pancreatic cancer is one instance of this pattern.

• Neurodegenerative diseases: Conditions such as ALS (Lou Gehrig’s disease), which Maa highlights, often raise acute questions because they involve long, frightening loss of bodily control while the mind remains intact.

• Other chronic illnesses and suffering: Some jurisdictions, particularly more permissive ones, allow assisted dying for severe, irreversible conditions that are not strictly terminal but cause intolerable suffering, such as advanced organ failure or certain chronic pain syndromes.

• Mental illness and non-terminal suffering: Here the debate is most intense. Some systems are moving cautiously toward allowing assisted dying when severe psychiatric conditions cause enduring suffering that has proven resistant to treatment. Others reject this, fearing that internal distress is too variable and that hope for future therapies remains.

Maa’s reference to Stephen Hawking underlines a key tension: some conditions that look hopeless at age 21 may still leave room for decades of meaning and scientific progress. That argument fuels caution about extending assisted dying across all forms of suffering, especially early in life.

Moral Problems: Autonomy, Harm, and the Role of Doctors

The moral landscape of assisted dying remains deeply divided. Maa’s AMA committee experience shows how differently people read the same practice:

• Some see physician-assisted suicide as a violation of the Hippocratic Oath’s prohibition on harming patients, and as too close to the history of doctors participating in coercive killing.

• Others see it as a way to honor patient autonomy and relieve unbearable suffering, especially when all other medical options have been exhausted.

• For many, the main concern is the risk of subtle pressure: people may request assisted dying because they feel like a burden on family or society, or because financial constraints make continued care feel unfair.

Maa’s story introduces more specific moral questions:

• Financial barriers: His friend’s distress over the $2,200 cost for the medications and physician illustrates how money can shape end-of-life choices. If assisted dying is expensive and unevenly covered, only some will have access, and decisions may be distorted by economic pressure.

• Family and witness trauma: Watching a loved one drink a lethal cocktail and die within minutes is emotionally different from being present at a natural death. Maa describes the ominous death rattle, the rapid loss of consciousness, and the unique weight of chatting with someone in the final half hour. This raises questions about how much emotional preparation families need, and whether their presence should be expected, discouraged, or carefully supported.

• Unused medication and safety: Some patients never take the lethal drugs they receive. That leaves potent medication in homes, raising concerns about storage, diversion, and disposal. Safe protocols are necessary to prevent misuse or accidental harm.

• Future cures and regret: The example of penicillin and future cancer treatments highlights a profound moral dilemma: if medicine continues to discover new therapies, some people who choose assisted dying today might have lived long enough to benefit from tomorrow’s breakthroughs. That possibility doesn’t resolve the present suffering but complicates the ethics of ending life while science moves forward.

How Different Systems Try to Solve These Problems

Jurisdictions that permit assisted dying use a variety of “guardrails” to reduce risks and reassure the public. While details differ, common safeguards include:

• Eligibility criteria: Limits on who can access assisted dying, often requiring adulthood, decision-making capacity, a serious and incurable condition, and either a terminal prognosis or enduring, intolerable suffering. Canada, for example, ties eligibility to age, capacity, and publicly funded healthcare, while debating the timing of access for mental illness as a sole diagnosis.

• Multiple assessments: Two or more independent clinicians must confirm that the person meets criteria, reducing the chance of a single misjudgment or conflict of interest.

• Waiting periods and repeated requests: Some regimes require a minimum time between the initial request and the final prescription or procedure, to ensure the choice is stable and not impulsive.

• Mandatory information and alternatives: Patients are typically informed about hospice, palliative care, and other options, so assisted dying is framed as one possibility among several, not the only “solution.”

• Reporting and oversight: Many systems require case reporting to a central authority and review by a committee or board, aiming to detect patterns, abuse, or overreach.

• Medication protocols and disposal: Guidelines exist to manage the lethal drugs safely, track their use, and ensure disposal of any unused medication.

Maa’s call for stronger guardrails suggests that these mechanisms may be necessary but not sufficient. He raises the idea of reducing financial barriers, reshaping expectations about family presence, addressing unused medication more rigorously, and reconsidering how deeply physicians themselves should be involved.

Should Physicians Be Involved at All?

The most fundamental question Maa poses is whether doctors should occupy the central role in assisted dying. He suggests one possible model in which physicians verify eligibility but then step back, leaving the delivery and procedural aspects to others such as pharmacists or coroners.

Arguments for physician involvement include:

• Doctors already manage life-support decisions, palliative sedation, and complex end-of-life care; assisted dying can be seen as another dimension of that responsibility.

• Physicians know the patient’s medical history and prognosis and are therefore best placed to judge eligibility and explain options.

• Their involvement offers professional oversight and an ethical framework, potentially preventing more chaotic or unregulated forms of assistance.

Arguments against deep physician involvement include:

• It risks blurring the line between healing and killing, undermining public trust in the medical profession.

• It may place heavy psychological burdens on clinicians, especially those who feel that their calling is to preserve life, not end it.

• It could institutionalize a practice that some fear might gradually extend to broader groups without sufficient safeguards.

Maa’s own Assisted Dying: Pioneers, Leaders, and the Question of Guardrails

Opening: One Death, Many Questions

Physician-assisted suicide has moved from a rare experiment at the margins of medicine to a growing feature of end-of-life care in many places. Yet the core questions remain unresolved: who should have access, under what safeguards, and whether doctors should be involved at all. John Maa’s recent account of watching his friend die through physician-assisted suicide brings these questions out of theory and into a living room, where a man with advanced pancreatic cancer drinks a lethal cocktail while his friends hold his hand and listen to his favorite song.

Maa describes not only his friend’s suffering but also the practical burdens: high out-of-pocket costs, the emotional impact on loved ones, and the uncertainty about whether physicians should do more to protect life, seek new treatments, or step back from the role of ending life. His story is one doorway into a wider international debate.

Historical Pioneers in Assisted Dying

Assisted dying did not emerge everywhere at once. Historically, a few jurisdictions acted decades before others and created models that still shape the debate.

• Switzerland is often cited as the earliest pioneer in assisted suicide, with legal space carved out as far back as the early 1940s. That framework allowed assistance in dying so long as the motive was not selfish, and it later gave rise to organizations that support people at the end of life, including some from abroad.

• In the United States, Oregon became the first state to adopt a physician-assisted dying law in the 1990s, the Death with Dignity Act, aimed at terminally ill patients who self-administer prescribed medication. That law, implemented in 1997, became the template for similar statutes elsewhere.

• The Netherlands is widely described as the first country to formally legalize euthanasia in the early 2000s, under strict conditions and reporting requirements. Belgium followed with its own euthanasia law, helping to establish Europe’s best-known euthanasia regimes.

These pioneers answered a question that had been mostly theoretical: can a modern legal system openly permit doctors or others to help people die without collapsing the boundaries between care and killing? Their answer was “yes, under conditions.”

Who Is Ahead Today in Access?

Today, the map of assisted dying looks very different. Several countries and subnational jurisdictions have adopted some form of assisted suicide or euthanasia, but the breadth of access varies greatly.

• Canada’s medical assistance in dying (MAID) regime is frequently noted as one of the more permissive contemporary frameworks, covering a broader range of medical conditions than the early U.S. state laws and continuing to evolve.

• Across Europe, a small group of states (such as the Netherlands, Belgium, Luxembourg, and others) now allow euthanasia or assisted dying under defined safeguards, often beyond narrow terminal-illness criteria.

• In the U.S., multiple states and Washington, D.C. have joined Oregon in legalizing physician-assisted dying, but the eligibility rules typically remain narrower, focused mainly on terminal illness and a short expected time to live.

In this sense, Switzerland is the historical pioneer, while countries like Canada and some European states are currently “ahead” in the breadth and operational scale of assisted dying. The spread is uneven, and there is no global consensus.

Why Assisted Dying Is Considered Necessary

Supporters of assisted dying often begin from the same point that Maa describes: the reality of severe, irreversible suffering at the end of life. His friend’s pancreatic cancer had progressed, treatments had failed, bowel obstructions required repeated hospitalization, and surgeons said nothing more could be done. In such situations, proponents argue that:

• Autonomy matters. A competent adult facing unbearable suffering should have the right to choose the timing and manner of death rather than be forced into prolonged decline.

• Compassion matters. When medicine can no longer cure or substantially relieve suffering, helping a patient avoid a drawn-out, painful end may be seen as a continuation of care rather than an abandonment of it.

• Reality matters. Even with good hospice and palliative care, some symptoms, losses of dignity, or forms of distress remain hard to control, and waiting can mean months of profound discomfort.

From this perspective, assisted dying is presented as a last-resort option for people whose lives have become dominated by suffering and for whom no realistic medical improvement is expected.

How Help Is Distributed Between Indications

Different systems distribute access to assisted dying across medical indications in very different ways. Common patterns include:

• Terminal cancer: In many regimes, advanced cancer is the leading indication for assisted dying, reflecting high symptom burden, poor prognosis, and patients’ awareness of progressive decline. Maa’s friend with pancreatic cancer is one instance of this pattern.

• Neurodegenerative diseases: Conditions such as ALS (Lou Gehrig’s disease), which Maa highlights, often raise acute questions because they involve long, frightening loss of bodily control while the mind remains intact.

• Other chronic illnesses and suffering: Some jurisdictions, particularly more permissive ones, allow assisted dying for severe, irreversible conditions that are not strictly terminal but cause intolerable suffering, such as advanced organ failure or certain chronic pain syndromes.

• Mental illness and non-terminal suffering: Here the debate is most intense. Some systems are moving cautiously toward allowing assisted dying when severe psychiatric conditions cause enduring suffering that has proven resistant to treatment. Others reject this, fearing that internal distress is too variable and that hope for future therapies remains.

Maa’s reference to Stephen Hawking underlines a key tension: some conditions that look hopeless at age 21 may still leave room for decades of meaning and scientific progress. That argument fuels caution about extending assisted dying across all forms of suffering, especially early in life.

Moral Problems: Autonomy, Harm, and the Role of Doctors

The moral landscape of assisted dying remains deeply divided. Maa’s AMA committee experience shows how differently people read the same practice:

• Some see physician-assisted suicide as a violation of the Hippocratic Oath’s prohibition on harming patients, and as too close to the history of doctors participating in coercive killing.

• Others see it as a way to honor patient autonomy and relieve unbearable suffering, especially when all other medical options have been exhausted.

• For many, the main concern is the risk of subtle pressure: people may request assisted dying because they feel like a burden on family or society, or because financial constraints make continued care feel unfair.

Maa’s story introduces more specific moral questions:

• Financial barriers: His friend’s distress over the $2,200 cost for the medications and physician illustrates how money can shape end-of-life choices. If assisted dying is expensive and unevenly covered, only some will have access, and decisions may be distorted by economic pressure.

• Family and witness trauma: Watching a loved one drink a lethal cocktail and die within minutes is emotionally different from being present at a natural death. Maa describes the ominous death rattle, the rapid loss of consciousness, and the unique weight of chatting with someone in the final half hour. This raises questions about how much emotional preparation families need, and whether their presence should be expected, discouraged, or carefully supported.

• Unused medication and safety: Some patients never take the lethal drugs they receive. That leaves potent medication in homes, raising concerns about storage, diversion, and disposal. Safe protocols are necessary to prevent misuse or accidental harm.

• Future cures and regret: The example of penicillin and future cancer treatments highlights a profound moral dilemma: if medicine continues to discover new therapies, some people who choose assisted dying today might have lived long enough to benefit from tomorrow’s breakthroughs. That possibility doesn’t resolve the present suffering but complicates the ethics of ending life while science moves forward.

How Different Systems Try to Solve These Problems

Jurisdictions that permit assisted dying use a variety of “guardrails” to reduce risks and reassure the public. While details differ, common safeguards include:

• Eligibility criteria: Limits on who can access assisted dying, often requiring adulthood, decision-making capacity, a serious and incurable condition, and either a terminal prognosis or enduring, intolerable suffering. Canada, for example, ties eligibility to age, capacity, and publicly funded healthcare, while debating the timing of access for mental illness as a sole diagnosis.

• Multiple assessments: Two or more independent clinicians must confirm that the person meets criteria, reducing the chance of a single misjudgment or conflict of interest.

• Waiting periods and repeated requests: Some regimes require a minimum time between the initial request and the final prescription or procedure, to ensure the choice is stable and not impulsive.

• Mandatory information and alternatives: Patients are typically informed about hospice, palliative care, and other options, so assisted dying is framed as one possibility among several, not the only “solution.”

• Reporting and oversight: Many systems require case reporting to a central authority and review by a committee or board, aiming to detect patterns, abuse, or overreach.

• Medication protocols and disposal: Guidelines exist to manage the lethal drugs safely, track their use, and ensure disposal of any unused medication.

Maa’s call for stronger guardrails suggests that these mechanisms may be necessary but not sufficient. He raises the idea of reducing financial barriers, reshaping expectations about family presence, addressing unused medication more rigorously, and reconsidering how deeply physicians themselves should be involved.

Should Physicians Be Involved at All?

The most fundamental question Maa poses is whether doctors should occupy the central role in assisted dying. He suggests one possible model in which physicians verify eligibility but then step back, leaving the delivery and procedural aspects to others such as pharmacists or coroners.

Arguments for physician involvement include:

• Doctors already manage life-support decisions, palliative sedation, and complex end-of-life care; assisted dying can be seen as another dimension of that responsibility.

• Physicians know the patient’s medical history and prognosis and are therefore best placed to judge eligibility and explain options.

• Their involvement offers professional oversight and an ethical framework, potentially preventing more chaotic or unregulated forms of assistance.

Arguments against deep physician involvement include:

• It risks blurring the line between healing and killing, undermining public trust in the medical profession.

• It may place heavy psychological burdens on clinicians, especially those who feel that their calling is to preserve life, not end it.

• It could institutionalize a practice that some fear might gradually extend to broader groups without sufficient safeguards.

Maa’s own stance leans toward a narrower medical role: physicians focusing on supporting terminal patients and seeking new cures, while any legal mechanism for ending life is carefully constrained and perhaps partly shifted to non-medical actors.

A Bipolar Perspective for the Public

For a wide public, the most honest article on assisted dying will probably need to hold two poles at once:

• On one side, the pioneers and current leaders show that it is possible to design assisted dying laws that function and that many patients, like Maa’s friend, experience as a meaningful and dignified choice.

• On the other side, stories like Maa’s expose the moral, emotional, and practical fragilities in those systems: money, family trauma, unused drugs, physician burden, and the unknown future of medicine.

The point is not to offer a final verdict, but to map the field clearly. Assisted dying now exists in many places. It is not going away. The real question is how societies will decide:

• Who may cross that threshold,

• Under what protections and supervision,

• With what role for physicians,

• And with what commitment to still seek cures and better palliative care for those who choose to live as long as they can.

Would you like this turned into a shorter op-ed version (about one newspaper page) or kept as a longer essay with more detail on specific countries?stance leans toward a narrower medical role: physicians focusing on supporting terminal patients and seeking new cures, while any legal mechanism for ending life is carefully constrained and perhaps partly shifted to non-medical actors.

A Bipolar Perspective for the Public

For a wide public, the most honest article on assisted dying will probably need to hold two poles at once:

• On one side, the pioneers and current leaders show that it is possible to design assisted dying laws that function and that many patients, like Maa’s friend, experience as a meaningful and dignified choice.

• On the other side, stories like Maa’s expose the moral, emotional, and practical fragilities in those systems: money, family trauma, unused drugs, physician burden, and the unknown future of medicine.

The point is not to offer a final verdict, but to map the field clearly. Assisted dying now exists in many places. It is not going away. The real question is how societies will decide:

• Who may cross that threshold,

• Under what protections and supervision,

• With what role for physicians,

• And with what commitment to still seek cures and better palliative care for those who choose to live as long as they can.

Would you like this turned into a shorter op-ed version (about one newspaper page) or kept as a longer essay with more detail on specific countries?

You can learn more by reading our e-book or listening to our audiobook

Mykola Iabluchanskyi together with Andriy Yabluchanskiy